A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients
Status:
Recruiting
Trial end date:
2024-06-28
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of 100 mg DRBP108 tablets in the treatment
of type 2 diabetes mellitus. A total of 750 subjects will be randomly allocated to three
groups: DRBP108, active comparator and placebo comparator, in a 3:1:1 ratio. The purpose of
this study is to evaluate whether 24 weeks of DRBP108 treatment will adequately reduce
hemoglobin A1C levels in T2DM subjects.